RESUMEN
OBJECTIVES: It has been reported that hepatic cytochrome P450 (CYP)2C9 and CYP3A4 are responsible for the metabolism of sildenafil and formation of its metabolite, N-desmethylsildenafil, in humans. However, in-vivo studies in rats have not been reported. METHODS: Sildenafil (20 mg/kg) was administered intravenously to rats pretreated with sulfaphenazole, cimetidine, quinine hydrochloride or troleandomycin, inhibitors of CYP2C6, CYP2C11, CYP2D subfamily and CYP3A1/2, respectively. In-vitro studies using rat liver microsomes were also performed. KEY FINDINGS: The area under the plasma-concentration time curve (AUC) was increased and clearance of sildenafil decreased in rats pretreated with cimetidine or troleandomycin. The AUC ratio for N-desmethylsildenafil (0-4 h) : sildenafil (0-infinity) was significantly decreased only in rats pretreated with cimetidine. Similar results were obtained in the in-vitro study using rat liver microsomes. CONCLUSIONS: Sildenafil is metabolised via hepatic CYP2C11 and 3A1/2, and N-desmethylsildenafil is mainly formed via hepatic CYP2C11 in rats. Thus, rats could be a good model for pharmacokinetic studies of sildenafil and N-desmethylsildenafil in humans.
Asunto(s)
Cimetidina/farmacología , Sistema Enzimático del Citocromo P-450/metabolismo , Inhibidores Enzimáticos/farmacología , Hígado/metabolismo , Inhibidores de Fosfodiesterasa/farmacocinética , Piperazinas/farmacocinética , Sulfonas/farmacocinética , Troleandomicina/farmacología , Animales , Área Bajo la Curva , Inactivación Metabólica , Masculino , Microsomas , Inhibidores de Fosfodiesterasa/metabolismo , Piperazinas/metabolismo , Purinas/metabolismo , Purinas/farmacocinética , Ratas , Ratas Sprague-Dawley , Citrato de Sildenafil , Sulfonas/metabolismoRESUMEN
Pharmacokinetics of amitriptyline and nortriptyline were evaluated after intravenous (2.5-10 mg/kg) and oral (10-100 mg/kg) administration of amitriptyline to rats. The hepatic, gastric, and intestinal first-pass effects of amitriptyline were also measured at a dose of 10 mg/kg. The areas under the plasma concentration-time curve (AUCs) of amitriptyline were dose-proportional following both intravenous and oral administration. After oral administration of amitriptyline, approximately 1.50% of the dose was not absorbed, the extent of absolute oral bioavalability (F) was approximately 6.30%, and the hepatic and intestinal first-pass effects of amitriptyline were approximately 9% and 87% of the oral dose, respectively. Although the hepatic first-pass effect was 78.9% after absorption into the portal vein, the value was only 9% of the oral dose due to considerable intestinal first-pass effect in rats. The low F of amitriptyline in rats was primarily attributable to considerable intestinal first-pass effect. This study proves the little contribution of considerable hepatic first-pass effect to low F of amitriptyline due to great intestinal first-pass effect in rats. The lower F value of amitriptyline in rats than that in humans (46 +/- 48%) was due to grater metabolism of amitriptyline in rats' liver and/or small intestine.
Asunto(s)
Amitriptilina/farmacocinética , Intestino Delgado/metabolismo , Hígado/metabolismo , Nortriptilina/farmacocinética , Administración Oral , Amitriptilina/administración & dosificación , Amitriptilina/sangre , Animales , Disponibilidad Biológica , Relación Dosis-Respuesta a Droga , Mucosa Gástrica/metabolismo , Inyecciones Intravenosas , Masculino , Nortriptilina/administración & dosificación , Nortriptilina/sangre , Ratas , Ratas Sprague-Dawley , Distribución TisularRESUMEN
Protein expression of the hepatic CYP2E1 has been reported to be increased in diabetic rats. This enzyme is the primary metabolizer of chlorzoxazone (CZX) to 6-hydroxychlorzoxazone (OH-CZX). Although patients with liver cirrhosis have a higher prevalence of diabetes mellitus, there have been no reported studies on the protein expression of CYP2E1 in rats induced to have liver cirrhosis and diabetes mellitus by injection of N-dimethylnitrosamine followed by streptozotocin [liver cirrhosis with diabetes mellitus (LCD) rats]. Thus, in the present study, the pharmacokinetics of CZX and OH-CZX were evaluated in LCD rats. Compared with control rats, LCD rats had significantly decreased (by 62%) total liver protein and significantly increased (by 124%) protein expression of CYP2E1, but the intrinsic clearance (Cl(int); formation of OH-CZX per milligram protein) was comparable in both groups of rats. As a result, the relative Cl(int) was also comparable for the two groups. Thus, OH-CZX formation in LCD and control rats was expected to be similar. As expected, after i.v. (20 mg/kg) and p.o. (50 mg/kg) administration of CZX, the area under the curve (AUC) of OH-CZX was comparable in control and LCD rats (i.v., 571 +/- 85.8 and 578 +/- 413 microg x min/ml, respectively; p.o., 1540 +/- 338 and 2170 +/- 1070 microg x min/ml, respectively). In LCD rats, the AUC(OH-CZX)/AUC(CZX) ratio was similar to the value in control rats after i.v. and p.o. administration. These results indicate that OH-CZX can be used as a chemical probe to assess the activity of CYP2E1 in LCD rats.
Asunto(s)
Clorzoxazona/análogos & derivados , Clorzoxazona/farmacocinética , Diabetes Mellitus Experimental/complicaciones , Cirrosis Hepática Experimental/complicaciones , Administración Oral , Animales , Área Bajo la Curva , Proteínas Sanguíneas/metabolismo , Clorzoxazona/administración & dosificación , Clorzoxazona/metabolismo , Cromatografía Líquida de Alta Presión , Diabetes Mellitus Experimental/fisiopatología , Infusiones Intravenosas , Riñón/fisiopatología , Hígado/fisiopatología , Cirrosis Hepática Experimental/fisiopatología , Masculino , Unión Proteica , Ratas , Ratas Sprague-Dawley , Bazo/fisiopatologíaRESUMEN
It has been reported that the expressions of hepatic microsomal cytochrome P450 (CYP) 1A1/2, 2B1/2 and 3A1/2 were not changed in rats with water deprivation for 72 h (rat model of dehydration) compared with the controls. It has been also reported that 1,3-dimethyluric acid (1,3-DMU) was formed from theophylline via CYP1A1/2 in rats. Hence, it could be expected that the formation of 1,3-DMU could be comparable between the two groups of rats. As expected, after both intravenous and oral administration of theophylline at a dose of 5 mg/kg to the rat model of dehydration, the AUC of 1,3-DMU was comparable to the controls. After both intravenous and oral administration of theophylline to the rat model of dehydration, the Cl(r) of both theophylline and 1,3-DMU was significantly slower than the controls. This could be due to significantly smaller urinary excretions of both theophylline and 1,3-DMU since the AUC of both theophylline and 1,3-DMU were comparable between the two groups of rats. The smaller urinary excretion of both theophylline and 1,3-DMU could be due to urine flow rate-dependent timed-interval renal clearance of both theophylline and 1,3-DMU in rats.
Asunto(s)
Broncodilatadores/farmacocinética , Teofilina/farmacocinética , Ácido Úrico/análogos & derivados , Privación de Agua/fisiología , Administración Oral , Animales , Área Bajo la Curva , Proteínas Sanguíneas/metabolismo , Broncodilatadores/administración & dosificación , Deshidratación/metabolismo , Semivida , Inyecciones Intravenosas , Masculino , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/metabolismo , Unión Proteica , Ratas , Ratas Sprague-Dawley , Teofilina/administración & dosificación , Ácido Úrico/administración & dosificación , Ácido Úrico/farmacocinéticaRESUMEN
It has been reported that the plasma (or serum) levels of albumin and globulins were lower and higher, respectively, than the serum levels in control rats. Hence, it could be expected that these changes could affect the renal clearance (Cl(r)) of methotrexate in Nagase analbuminemic rats (NARs) due to changes in plasma protein binding values. Therefore, methotrexate at a dose of 100 mg/kg was administered intravenously to control rats and NARs. The plasma protein binding of methotrexate in NARs was significantly greater (29.4% increase) than the controls, probably due to the considerable binding of the drug (34.2%) to 1.8% beta-plus 0.63% gamma-globulins. The Cl(r) of methotrexate in NARs was significantly slower (36.1% decrease) than the controls, due to the significantly smaller Ae(0-24h) (25.8% decrease). The smaller Ae(0-24h) could be due to the significantly smaller free (unbound to plasma proteins) fractions of methotrexate in plasma (13.8% decrease) in NARs, since methotrexate was mainly excreted in the urine via glomerular filtration. However, the Cl(nr) values were comparable between the control rats and NARs. This could be because methotrexate is not metabolized considerably via hepatic CYP isozymes based on control rats pretreated with SKF 525-A (a nonspecific inhibitor of hepatic CYP isozymes in rats).
Asunto(s)
Metotrexato/farmacocinética , Albúmina Sérica/deficiencia , Albúmina Sérica/genética , Animales , Tasa de Filtración Glomerular , Infusiones Intravenosas , Masculino , Metotrexato/administración & dosificación , Proadifeno/farmacología , Unión Proteica , Ratas , Ratas Mutantes , Ratas Sprague-Dawley , Albúmina Sérica/metabolismoRESUMEN
DA-7218 (a prodrug of DA-7157), a new oxazolidinone, was hydrolysed via phosphatase to form its active metabolite, DA-7157, in rats. The pharmacokinetic parameters of DA-7218 and DA-7157 were evaluated after intravenous (5, 10 and 20 mg kg(-1)) and oral (20, 50 and 100 mg kg(-1)) administration of DA-7218 to rats. DA-7218 and DA-7157 exhibited dose-proportional pharmacokinetics after both intravenous and oral administration of DA-7218 to rats. The stability of DA-7218 and DA-7157, blood partition of DA-7157, and the plasma protein binding of DA-7157 were also evaluated. DA-7218 was unstable in rat blood, plasma, bile and liver homogenates, but DA-7157 was stable, suggesting that DA-7218 is hydrolysed via phosphatase. DA-7157 rapidly reached equilibrium between plasma and blood cells, and the mean equilibrium plasma-to-blood cells ratio was 3.18, indicating that binding of DA-7157 to blood cells was not considerable. The protein binding of DA-7157 in fresh rat plasma was 93.4%.
Asunto(s)
Antibacterianos/farmacocinética , Organofosfatos/farmacocinética , Oxazoles/farmacocinética , Oxazolidinonas/farmacocinética , Profármacos/farmacocinética , Tetrazoles/farmacocinética , Administración Oral , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Relación Dosis-Respuesta a Droga , Estabilidad de Medicamentos , Inyecciones Intravenosas , Masculino , Organofosfatos/administración & dosificación , Organofosfatos/sangre , Oxazoles/administración & dosificación , Oxazoles/sangre , Oxazolidinonas/administración & dosificación , Oxazolidinonas/sangre , Profármacos/administración & dosificación , Unión Proteica , Ratas , Ratas Sprague-Dawley , Tetrazoles/administración & dosificación , Tetrazoles/sangreRESUMEN
It has been reported that plasma albumin concentrations were significantly lower in cancer patients than those in the healthy volunteers, and the expression and mRNA level of hepatic microsomal cytochrome P450 (CYP) 1A2 increased in mutant Nagase analbuminemic rats (NARs). After intravenous administration of 5-fluorouracil at a dose of 30 mg/kg to NARs, the time-averaged nonrenal clearance (Clnr) of the drug was significantly faster than the controls (51.3 versus 28.8 ml/min/kg), possibly due to an increase in the expression and mRNA level of CYP1A2 in NARs. In order to determine whether 5-fluorouracil is metabolized via CYP1A2 in male Sprague-Dawley rats, the rats were pretreated with 3-methylcholanthrene (a main inducer of CYP1A1/2 in rats). The Clnr of 5-fluorouracil was significantly faster (34.3 versus 27.3 ml/min/kg) in rats pretreated with 3-methylcholanthrene. The aforementioned data indicate that CYP1A is involved in the metabolism of 5-fluorouracil in rats.
Asunto(s)
Acetilglucosaminidasa/genética , Antimetabolitos/farmacocinética , Citocromo P-450 CYP1A1/metabolismo , Citocromo P-450 CYP1A2/metabolismo , Fluorouracilo/farmacocinética , Albúmina Sérica/deficiencia , Animales , Área Bajo la Curva , Proteínas Sanguíneas/metabolismo , Cromatografía Líquida de Alta Presión , Inhibidores Enzimáticos/farmacología , Semivida , Inyecciones Intravenosas , Masculino , Metilcolantreno/farmacología , Microdiálisis , Proadifeno/farmacología , Unión Proteica , Ratas , Ratas Sprague-DawleyRESUMEN
Pharmacokinetic parameters of chlorzoxazone (CZX) and its main metabolite, 6-hydroxychlorzoxazone (OH-CZX), were compared after intravenous (20 mg/kg) and oral (50 mg/kg) administration of CZX in rat model of diabetes induced by alloxan (DMIA) or streptozotocin (DMIS), and their respective control rats. In both rat models of diabetes, the expression and mRNA level of CYP2E1 increased, and CZX was metabolized to OH-CZX via CYP2E1 in rats. Hence, it could be expected that formation of OH-CZX increased in both rat models of diabetes. As expected, after intravenous (80.5% and 74.4% increase in rat models of DMIA and DMIS, respectively) and oral (55.6% and 70.5% increase, respectively) administration of CZX, the AUC of OH-CZX was significantly greater than their respective control rats. Since, CZX is an intermediate hepatic extraction ratio drug, the greater AUC values of OH-CZX (the significantly faster CL(NR) of CZX) in both rat models of diabetes could be supported by significantly faster CL(int) for the formation of OH-CZX (75.9% and 129% increase for rat models of DMIA and DMIS, respectively) and significantly greater free fractions of CZX in plasma (51.9% and 58.9% increase, respectively). Also it was reported that hepatic blood flow rate was faster in male Wister rat model of DMIS.
Asunto(s)
Clorzoxazona/análogos & derivados , Clorzoxazona/administración & dosificación , Clorzoxazona/farmacocinética , Citocromo P-450 CYP2E1/metabolismo , Diabetes Mellitus Experimental/metabolismo , Relajantes Musculares Centrales/administración & dosificación , Relajantes Musculares Centrales/farmacocinética , Animales , Biotransformación , Proteínas Sanguíneas/metabolismo , Clorzoxazona/sangre , Clorzoxazona/metabolismo , Cromatografía Líquida de Alta Presión , Citocromo P-450 CYP2E1/biosíntesis , Inducción Enzimática , Inyecciones Intravenosas , Masculino , Microsomas Hepáticos/metabolismo , Unión Proteica , ARN Mensajero/biosíntesis , Ratas , Ratas Sprague-DawleyRESUMEN
Pharmacokinetics of sildenafil after intravenous and oral administration at various doses and first-pass effect at 30 mg/kg were evaluated in rats. After intravenous administration (10, 30, and 50mg/kg), the dose-normalized AUC values were proportional to intravenous doses studied. However, after oral administration (10, 30, and 100mg/kg), the dose-normalized AUC values increased significantly with increasing doses, possibly due to saturation of metabolism of sildenafil in rat intestinal tract. After oral administration (30 mg/kg), approximately 0.626% was not absorbed and F was 14.6%. The AUC after intragastric administration was significantly smaller (71.4% decrease) than that after intraportal administration, however, the values were not significantly different between intragastric and intraduodenal administration. The above data suggested that intestinal first-pass effect of sildenafil was approximately 71% of oral dose in rats. The AUC values after intraportal administration were significantly smaller (49% decrease) than that after intravenous administration. This suggested that hepatic first-pass effect of sildenafil after absorption into the portal vein was approximately 49% of oral dose in rats (approximately 49% was equivalent to approximately 13.7% of oral dose). The low F of sildenafil at a dose of 30 mg/kg in rats could be mainly due to considerable intestinal first-pass effect.
Asunto(s)
Mucosa Intestinal/metabolismo , Hígado/metabolismo , Inhibidores de Fosfodiesterasa/farmacocinética , Piperazinas/farmacocinética , Administración Oral , Animales , Área Bajo la Curva , Relación Dosis-Respuesta a Droga , Infusiones Intravenosas , Intubación Gastrointestinal , Masculino , Inhibidores de Fosfodiesterasa/administración & dosificación , Inhibidores de Fosfodiesterasa/sangre , Piperazinas/administración & dosificación , Piperazinas/sangre , Purinas , Ratas , Ratas Sprague-Dawley , Citrato de Sildenafil , SulfonasRESUMEN
A series of experiments using various inducers and inhibitors of the hepatic microsomal cytochrome P450 (CYP) isozymes were conducted to find CYP isozymes responsible for the metabolism of omeprazole in male Sprague-Dawley rats. Omeprazole, 20 mg/kg, was administered intravenously. In rats pretreated with SKF 525-A (a nonspecific CYP isozyme inhibitor in rats), the time-averaged nonrenal clearance (Cl(nr)) was significantly slower (77.1% decrease) than that in untreated rats. This indicated that omeprazole is metabolized via CYP isozymes in rats. Hence, rats were pretreated with various enzyme inducers and inhibitors. In rats pretreated with 3-methylcholanthrene and dexamethasone (main inducers of CYP1A1/2 and 3A1/2 in rats, respectively), the Cl(nr) values were significantly faster (43.8% and 26.3% increase, respectively). In rats pretreated with troleandomycin and quinine (main inhibitors of CYP3A1/2 and 2D1 in rats, respectively), the Cl(nr) values were significantly slower (20.9% and 12.9% decrease, respectively). However, the Cl(nr) values were not significantly different in rats pretreated with orphenadrine, isoniazid and sulfaphenazole (main inducers of CYP2B1/2 and 2E1, and a main inhibitor of 2C11, respectively, in rats) compared with those of respective control rats. The above data suggested that omeprazole could be mainly metabolized via CYP1A1/2, 3A1/2 and 2D1 in male rats.
Asunto(s)
Antiulcerosos/farmacocinética , Hidrocarburo de Aril Hidroxilasas/metabolismo , Microsomas Hepáticos/enzimología , Omeprazol/farmacocinética , Animales , Antiulcerosos/administración & dosificación , Hidrocarburo de Aril Hidroxilasas/antagonistas & inhibidores , Dexametasona/farmacología , Inducción Enzimática , Inhibidores Enzimáticos/farmacología , Inyecciones Intravenosas , Masculino , Metilcolantreno/farmacología , Microsomas Hepáticos/efectos de los fármacos , Omeprazol/administración & dosificación , Proadifeno/farmacología , Ratas , Ratas Sprague-DawleyRESUMEN
Pharmacokinetic parameters of oltipraz were compared after intravenous (10 mg/kg) and oral (50 mg/kg) administration to control male Sprague-Dawely rats and mutant Nagase analbuminemic rats (NARs). In NARs, the expression and mRNA level of CYP1A2 increased, and oltipraz was mainly metabolized via CYP1A1/2, 2B1/2, 2C11, 201, and 3A1/2 in male rats. Hence, it may be expected that the CL of oltipraz would be significantly faster in NARs. This was proven by the following results. After intravenous administration, the CL of oltipraz was significantly faster in NARs (125% increase) than controls due to significantly greater free fractions (unbound to plasma proteins) of oltipraz (197% increase) and significantly faster CL(int) for the disappearance of oltipraz (11.4% increase) in NARs, since oltipraz is an intermediate hepatic extraction ratio drug in rats. The V(ss) was significantly larger in NARs (109% increase) and this could be due to significant increase in free fractions of oltipraz in NARs. After oral administration, the AUC of oltipraz was also significantly smaller in NARs (61.9% decrease). This could also be due to significant increase in free fractions of oltipraz and significantly faster CL(int) in NARs. However, this was not due to decrease in absorption in NARs.
Asunto(s)
Acetilglucosaminidasa/genética , Albúminas/deficiencia , Pirazinas/farmacocinética , Esquistosomicidas/farmacocinética , Administración Oral , Albúminas/genética , Animales , Área Bajo la Curva , Proteínas Sanguíneas/metabolismo , Citocromo P-450 CYP1A2/metabolismo , Diálisis , Semivida , Inyecciones Intravenosas , Masculino , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Mutación/fisiología , Unión Proteica , Ratas , Ratas Sprague-Dawley , Tionas , TiofenosRESUMEN
Pharmacokinetics and therapeutic effects of oltipraz were evaluated after consecutive (once per day at 30 mg/kg/day for 7 and 14 days) or intermittent (once per week at 100 mg/kg/week for 1-3 weeks) oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. The AUC of oltipraz was significantly greater in cirrhotic rats than controls (890 compared with 270 microg . min/mL) due to impaired liver function in cirrhotic rats. However, the AUC values after consecutive 7 (421 compared with 753 microg . min/mL) and 14 (309 compared with 821 microg . min/mL) days oral administration of oltipraz in cirrhotic rats were significantly smaller than those in respective vehicle-treated cirrhotic rats. Moreover, the AUC values after intermittent 2 and 3 weeks in cirrhotic rats were also significantly smaller than that in 1 week vehicle-treated cirrhotic rats (2370 and 1690 compared with 4760 microg . min/mL). This could be due to induction of CYP isozymes and considerably greater numbers of normal liver cells in cirrhotic rats by oral administration of oltipraz. Improved liver function by oltipraz in cirrhotic rats was proved by liver microscopy; livers are free of significant fibrosis, although evidence of bridging necrosis is still present in many rats.
Asunto(s)
Pirazinas/farmacocinética , Pirazinas/uso terapéutico , Esquistosomicidas/farmacocinética , Esquistosomicidas/uso terapéutico , Administración Oral , Alquilantes , Animales , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Creatinina/metabolismo , Dimetilnitrosamina , Semivida , Hematócrito , Hígado/metabolismo , Cirrosis Hepática/inducido químicamente , Cirrosis Hepática/metabolismo , Masculino , Tamaño de los Órganos/efectos de los fármacos , Pirazinas/toxicidad , Ratas , Ratas Wistar , Esquistosomicidas/toxicidad , Tionas , TiofenosRESUMEN
The pharmacokinetic parameters of DA-7867 were compared after intravenous and oral administration at a dose of 10 mg/kg in control rats and in rats with water deprivation for 72 h (rat model of dehydration). After intravenous administration in the rat model of dehydration, the Cl(nr) (0.654 versus 0.992 ml/min/kg) and Cl(r) (0.0273 versus 0.0784 ml/min/kg) values were significantly slower than in the controls. The slower Cl(nr) could be due mainly to a significantly smaller total amount of unchanged DA-7867 recovered from the gastrointestinal tract at 24 h (GI(24 h): 5.16% versus 9.21% of intravenous dose) due to impaired liver function in the rat model of dehydration. The slower Cl(r) could be due mainly to a significantly smaller 24 h urinary excretion of unchanged drug (Ae(0-24 h): 4.41% versus 7.75% of intravenous dose) due to urine flow rate-dependent Cl(r) of DA-7867 in the rat model of dehydration. Hence, the Cl was significantly slower in the rat model of dehydration (0.677 versus 1.07 ml/min/kg). After intravenous administration in the rat model of dehydration, the V(ss) of DA-7867 was significantly smaller than in the controls (396 versus 506 ml/kg) due mainly to significantly smaller free (unbound to plasma proteins) fractions of DA-7867 in plasma (6.90% versus 29.2%) in the rat model of dehydration. After oral administration in the rat model of dehydration, the AUC was significantly greater than that in controls (10800 versus 7060 microg min/ml) due mainly to a significantly smaller Ae(0-24 h) than in controls (3.50% and 6.17% of oral dose).
Asunto(s)
Oxazolidinonas/farmacocinética , Privación de Agua/fisiología , Administración Oral , Animales , Área Bajo la Curva , Proteínas Sanguíneas/metabolismo , Nitrógeno de la Urea Sanguínea , Deshidratación/fisiopatología , Modelos Animales de Enfermedad , Ingestión de Alimentos/efectos de los fármacos , Inyecciones Intravenosas , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Tasa de Depuración Metabólica , Tamaño de los Órganos/efectos de los fármacos , Oxazolidinonas/administración & dosificación , Oxazolidinonas/sangre , Ratas , Ratas Sprague-Dawley , Factores de Tiempo , Distribución Tisular , Micción/efectos de los fármacos , Pérdida de Peso/efectos de los fármacosRESUMEN
Gender differences in the pharmacokinetics of DA-6034 were evaluated after intravenous and oral administration at a dose of 50 mg/kg to male and female Sprague-Dawley rats. After intravenous administration to male rats, although the total area under the plasma concentration-time curve from time zero to time infinity of DA-6034 was not significantly different between male and female rats, the plasma concentrations of DA-6034 were lower from 30 min to 480 min, the mean residence time was significantly shorter (6.28 versus 12.2 min), the percentage of intravenous dose of DA-6034 excreted in 24 h urine as unchanged drug was significantly greater (14.4% versus 10.5% of intravenous dose). After oral administration, the pharmacokinetic parameters of DA-6034 were not significantly different between male and female rats.
Asunto(s)
Flavonoides/farmacocinética , Administración Oral , Animales , Femenino , Flavonoides/administración & dosificación , Inyecciones Intravenosas , Masculino , Ratas , Ratas Sprague-Dawley , Factores SexualesRESUMEN
The pharmacokinetic parameters of DA-7867 were compared after intravenous and oral administration at a dose of 10 mg/kg to control rats and rats with acute renal failure induced by uranyl nitrate (rats with U-ARF). After intravenous administration in rats with U-ARF, the time-averaged total body clearance (Cl) was significantly faster (2.45 versus 0.932 ml/min/kg) than controls due to significantly faster nonrenal clearance (2.25 versus 0.855 ml/min/kg) in rats with U-ARF. The faster nonrenal clearance could be due to significantly greater gastrointestinal (including biliary) excretion; the amount of unchanged DA-7867 recovered from the entire gastrointestinal tract at 24 h was significantly greater (30.3% versus 9.38% of intravenous dose) in rats with U-ARF. In rats with U-ARF, the Vss was significantly larger (1420 ml/kg compared with 580 ml/kg), but this was not due to a difference in plasma protein binding; the values were comparable between the two groups of rats. After oral administration to rats with U-ARF, the total area under the plasma concentration-time from time zero to time infinity (AUC) of DA-7867 was significantly smaller than the controls (2560 microg min/ml versus 7440 microg min/ml), and this was not due mainly to a decrease in absorption from the gastrointestinal tract in rats with U-ARF.
Asunto(s)
Lesión Renal Aguda/metabolismo , Antiinfecciosos/farmacocinética , Oxazolidinonas/farmacocinética , Lesión Renal Aguda/inducido químicamente , Administración Oral , Animales , Antiinfecciosos/administración & dosificación , Inyecciones Intravenosas , Masculino , Oxazolidinonas/administración & dosificación , Ratas , Ratas Sprague-Dawley , Distribución Tisular , Nitrato de UraniloRESUMEN
The changes in pharmacokinetics of DA-8159 by omeprazole with respect to inhibition of CYP3A1/2 in rats were evaluated. After oral administration of DA-8159 at dose of 30 mg/kg to rats pretreated with oral omeprazole at 30 mg/kg for 1 week, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) of DA-8159 was significantly greater (37.5% increase) than that in control rats. This could be due to inhibition of metabolism of DA-8159 by inhibition of CYP3A1/2 by omeprazole. The AUC(DA-8164 (a metabolite of DA-8159))/AUC(DA-8159) ratio was also smaller (32.4% decrease) with omeprazole. After oral administration of DA-8159 at a dose of 30 mg/kg to rats without or with cola beverage, the pharmacokinetic parameters of DA-8159 and DA-8164 were not significantly different between two groups of rats. This suggested that cola beverage did not have any considerable effects on CYP3A1/2 in rats.
Asunto(s)
Bebidas , Cola , Inhibidores Enzimáticos/farmacología , Omeprazol/farmacología , Pirimidinas/farmacocinética , Administración Oral , Animales , Área Bajo la Curva , Hidrocarburo de Aril Hidroxilasas/antagonistas & inhibidores , Citocromo P-450 CYP3A , Interacciones Farmacológicas , Masculino , Proteínas de la Membrana/antagonistas & inhibidores , Tasa de Depuración Metabólica , Erección Peniana/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , SulfonamidasRESUMEN
Effects of diabetes mellitus induced by streptozotocin (DMIS) on the pharmacokinetics of DA-7867 were investigated after i.v. and oral administration (10mg/kg) to control Sprague-Dawley rats and DMIS rats (at 7th and 29th days after administration of streptozotocin, 45mg/kg). After i.v. administration to DMIS rats, the AUC(0-infinity) values were significantly smaller (50.7 and 64.8% decrease for 7th and 29th days, respectively); this could be due to significantly faster Cl values in the rats (127 and 183% increase for 7th and 29th days, respectively). The faster Cl values were mainly due to significantly greater amount of unchanged drug excreted in 24-h urine (Ae(0-24h)). The greater Ae(0-24h) in DMIS rats could be due to urine flow rate-dependent renal clearance of DA-7867. After oral administration to DMIS rats, the AUC(0-infinity) values were also significantly smaller (61.3 and 72.6% decrease for 7th and 29th days, respectively); this could also be mainly due to significantly greater Ae(0-24h) in the rats. Streptozotocin-induced hepatotoxicity did not influence considerably on the pharmacokinetics of DA-7867 at 7th day when compared with those at 29th day.
Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Oxazolidinonas/farmacocinética , Administración Oral , Animales , Área Bajo la Curva , Inyecciones Intravenosas , Masculino , Tasa de Depuración Metabólica , Oxazolidinonas/administración & dosificación , Ratas , Ratas Sprague-Dawley , Estreptozocina , Factores de TiempoRESUMEN
Effects of cysteine on the pharmacokinetics of oltipraz were investigated after iv (10 mg/kg) and oral (30 mg/kg) administration to male control, protein-calorie malnutrition (PCM), and PCM with oral cysteine supplementation (PCMC) rats. It was reported that oltipraz was mainly metabolized via hepatic CYP1A1/2, 2B1/2, 2C11, 3A1/2, and 2D1 in male rats. The expression and mRNA levels of CYP1A2, 2C11, and 3A1/2 were also reported to decrease in male PCM rats compared with controls. Interestingly, the decreased CYP isozymes in PCM rats returned fully or partially to controls by oral cysteine supplementation (PCMC rats). Hence, it would be expected that in PCM rats, some pharmacokinetic parameters of oltipraz are fully or partially returned to controls by cysteine. This was proven by the following parameters in PCMC rats: the AUC (328, 782, and 416 mug min/mL for control, PCM, and PCMC rats, respectively, after iv administration, and 223, 456, and 242 mug min/mL after oral administration), terminal half-life (130, 212, and 143 min), mean residence time (MRT) (149, 299, and 189 min), and in vitro CL(int) (0.181, 0.107, and 0.153 mL/min/mg protein) were fully returned to controls, and CL and CL(NR) values were partially returned to controls.
Asunto(s)
Cisteína/farmacología , Desnutrición Proteico-Calórica/metabolismo , Pirazinas/farmacocinética , Esquistosomicidas/farmacocinética , Animales , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Inyecciones Intravenosas , Masculino , Microsomas Hepáticos/metabolismo , Ratas , Ratas Sprague-Dawley , Tionas , TiofenosRESUMEN
It was reported that the mean value of the extent of absolute oral bioavailability (F) of oltipraz at a dose of 20 mg/kg was 41.2% and only 2.68% of the oral dose was unabsorbed from the gastrointestinal tract in rats. Hence, the low F in rats could be due to considerable first-pass (gastric, intestinal and hepatic) effects. Hence, the first-pass effects of oltipraz were measured after intravenous, intraportal, intragastric and intraduodenal administration of the drug at a dose of 20 mg/kg to rats. The total area under the plasma concentration-time curve from time zero to time infinity (AUC) values between intragastric and intraduodenal administration (213 and 212 microg min/ml) in rats were almost similar, but the values were significantly smaller than that after intraportal administration (316 microg min/ml) in rats, indicating that gastric first-pass effect was almost negligible (due to negligible absorption of oltipraz from rat stomach), but the intestinal first-pass effect of oltipraz was considerable, approximately 32% of the oral dose. The hepatic first-pass effect of oltipraz was approximately 40% based on AUC values between intravenous and intraportal administration (319 versus 536 microg min/ml). Since approximately 65% of the oral oltipraz was absorbed into the portal vein, the value of 40% was equivalent to 25% of the oral dose. The low F of oltipraz in rats was mainly due to considerable hepatic and intestinal first-pass effects.
Asunto(s)
Mucosa Intestinal/metabolismo , Hígado/metabolismo , Pirazinas/administración & dosificación , Pirazinas/farmacocinética , Administración Oral , Animales , Bilis/metabolismo , Disponibilidad Biológica , Duodeno , Mucosa Gástrica/metabolismo , Inyecciones Intravenosas , Masculino , Tasa de Depuración Metabólica , Vena Porta , Pirazinas/sangre , Ratas , Ratas Sprague-Dawley , Tionas , Tiofenos , Distribución TisularRESUMEN
Dose-independent pharmacokinetics of oltipraz after intravenous and/or oral administration at various doses to mice, rats, rabbits and dogs were evaluated. After both intravenous and/or oral administration of oltipraz to mice (5, 10 and 20 mg/kg for intravenous and 15, 30 and 50 mg/kg for oral administration), rats (5, 10 and 20 mg/kg for intravenous and 25, 50 and 100 mg/kg for oral administration), rabbits (5, 10 and 30 mg/kg for intravenous administration) and dogs (5 and 10 mg/kg for intravenous and 50 and 100 mg/kg for oral administration), the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values of oltipraz were dose-proportional in all animals studied. Animal scale-up of some pharmacokinetics parameters of oltipraz was also performed based on the parameters after intravenous administration at a dose of 10 mg/kg to mice, rats, rabbits and dogs. Linear relationships were obtained between log time-averaged total body clearance (Cl) x maximum life-span potential (MLP) (1 year/h) and log species body weight (W) (kg) (r=0.999; p=0.0015), log Cl (l/h) and log W (kg) (r=0.979; p=0.0209), and log apparent volume of distribution at steady state (V(ss)) (l) and log W (kg) (r=0.999; p=0.0009). The corresponding allometric equations were ClxMLP=49.8 W(0.861), Cl=5.20 W(0.523) and V(ss)=4.46 W(0.764). Interspecies scale-up of plasma concentration-time data for the four species using pharmacokinetic time of dienetichron resulted in similar profiles. In addition, concentrations of oltipraz in a plasma concentration-time profile for humans predicted using the four animal data fitted to the dienetichron time transformation of animal data.